TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a TrialRohit Loomba, George Kemble, Marie O’Farrell et al.|Gastroenterology|2021Cited by 216
Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USAAlexander H. Yang, Rohit Loomba, Monica A. Tincopa et al.|Gut|2024Cited by 54
Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of <scp>MetALD</scp> Versus <scp>MASLD</scp>: A Prospective StudyFederica Tavaglione, Rohit Loomba, Maral Amangurbanova et al.|Alimentary Pharmacology & Therapeutics|2025Cited by 38
Low liver fat in non‐alcoholic steatohepatitis‐related significant fibrosis and cirrhosis is associated with <scp>hepatocellular carcinoma</scp>, decompensation and mortalitySung Won Lee, Rohit Loomba, Daniel Q. Huang et al.|Alimentary Pharmacology & Therapeutics|2023Cited by 24
An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical PracticeLuis Antonio Diaz, Rohit Loomba, Veeral Ajmera et al.|Clinical Gastroenterology and Hepatology|2025Cited by 16